HIV Preexposure Prophylaxis in the Time of COVID-19: How a Robust and Responsive HIV Preexposure Prophylaxis Intervention Can Avert Loss of HIV Prevention Coverage During a Global Pandemic

J Acquir Immune Defic Syndr. 2021 May 1;87(1):e173-e176. doi: 10.1097/QAI.0000000000002652.

Authors

Parya Saberi¹, Kristin Ming¹, J Carlo Hojilla², Hyman M Scott³, Torsten B Neilands¹

Affiliations

¹ Division of Prevention Science, University of California, San Francisco, San Francisco, CA.
² Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA.
³ San Francisco Department of Public Health, Bridge HIV, San Francisco, CA.

No abstract available

Publication types

Letter

MeSH terms

Adult
Anti-HIV Agents / therapeutic use
COVID-19 / epidemiology*
Female
HIV Infections / prevention & control*
Humans
Male
Middle Aged
Pandemics
Pre-Exposure Prophylaxis / methods*
SARS-CoV-2 / isolation & purification
Young Adult

Substances

Anti-HIV Agents

Grants and funding